News coverage about Assembly Biosciences (NASDAQ:ASMB) has trended somewhat positive this week, according to Accern Sentiment Analysis. Accern ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Assembly Biosciences earned a news impact score of 0.19 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.6123853202068 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- Assembly Biosciences (ASMB) Cut to Sell at BidaskClub (americanbankingnews.com)
- Assembly Biosciences (ASMB) Expected to Post Quarterly Sales of $1.88 Million (americanbankingnews.com)
- Assembly Biosciences (ASMB) Says ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at EASL (streetinsider.com)
- Assembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome (finance.yahoo.com)
- William R. Ringo Sells 1,000 Shares of Assembly Biosciences (ASMB) Stock (americanbankingnews.com)
Assembly Biosciences stock opened at $44.61 on Friday. Assembly Biosciences has a one year low of $18.60 and a one year high of $67.36.
In related news, Director William R. Ringo sold 1,000 shares of the company’s stock in a transaction on Thursday, March 1st. The stock was sold at an average price of $56.37, for a total transaction of $56,370.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders have sold 3,000 shares of company stock valued at $152,550. 19.60% of the stock is owned by company insiders.
About Assembly Biosciences
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.